Timeline of Key Events
The Atturos team is now actively seeking seed investment from individuals through a series of tax efficient schemes including the BES and EII initiatives. If you are interested please don’t hesitate to contact Mike.
OCProDx and other products
|Atturos Secures Place in final of 2017 AIB Start-Up Academy
Submission of H2020 SME Instrument Phase 2 application
|Atturos Claim “Most Investible Start-Up” Award at EBAN Event||Nov 2016|
|Aug 2016||Initial results from second evaluation study in multiethnic cohort.|
Atturos engages with Business Mentor support from EU.
Atturos team complete H2020 Phase 1 project and initial business plan. We are using the business plan to raise investment in Atturos and are currently engaged in active discussions with several individual and institutional investors.
|June 2016||New high sensitivity QQQ installed in Biomarker Evaluation Laboratory.|
Atturos holds a series of innovative Brainstorming Sessions chaired by Frost & Sullivan – attendees include patients, clinicians, scientists, entrepreneurs and international business leaders.
Atturos website launched.
|Atturos Founder redeems UK USS pension fund to release capital to investment to Atturos.||April 2016||Academic collaboration agreement with Agilent.|
|Founding shareholders identified and agree seed investment.||Jan 2016|
|Atturos receives EU H2020 SME Instrument Phase 1.||Nov 2015|
|Atturos applies for EU H2020 SME Instrument Phase 1.||Sep 2015|
|Aug 2015||With St Luke’s Hospital, Pennington and team hold Prostate Cancer Patient research awareness event.|
|July 2015||Enterprise Ireland Commercialisation Fund awarded with the aim of supporting the technical and clinical evaluation of OCProDx.|
|June 2015||International patent application WO2015/092046 published.|
Pennington and Team establish dedicated MRM Biomarker Evaluation Laboratory in UCD Conway Institute.
MIAMI FP7 programme awarded: Pennington and Fitzgerald continue discovery and evaluation of protein biomarkers for inflammatory arthritis
|Atturos founded with support from Grant Thornton, Dublin Office.||Dec 2014||International filing of OCProDx biomarkers patent PCT/EP2014/078914.|
|Steve presents Atturos elevator pitch at BioConnect Ireland Event and meets Mike Feeney.||Oct 2014|
|Steve Pennington and Brian Flatley attend NovaUCD VentureLaunch programme.||Sept 2014|
|2010 – 2013||With funding from various agencies including the Irish Cancer Society, Pennington and team undertake LC-MS/MS discovery of serum protein biomarkers, MRM development and initial evaluation studies to develop OCProDx biomarker candidate panel.|
|2006||Armstrong and Pennington begin St Luke’s Institute for Cancer Research (SLICR) funded translational proteomic study as part of ICORG 06-15. Collecting longitudinal patient samples for protein biomarker discovery.|
|2005 – 2010||Pennington team develop expertise in MRM and label-free LC-MS/MS|